DDInter1515 DDInter1658
A synthetic anti-inflammatory glucocorticoid derived from [cortisone]. It is biologically inert and converted to [prednisolone] in the liver. Prednisone was granted FDA approval on 21 February 1955.
Selpercatinib is a kinase inhibitor with enhanced specificity for RET tyrosine kinase receptors (RTKs) over other RTK classes.[A202055, A202052, L13604] Enhanced RET (Rearranged during transfection) oncogene expression is a hallmark of many cancers. Although multikinase inhibitors, including [cabozantinib], [ponatinib], [sorafenib], [sunitinib], and [vandetanib], have shown efficacy in RET-driven cancers, their lack of specificity is generally associated with substantial toxicity. Selpercatinib (LOXO-292) and pralsetinib (BLU-667) represent the first generation of specific RET RTK inhibitors for the treatment of RET-driven cancers.[A202049, A202055, A202052, L13604] Although selpercatinib is currently still under investigation in clinical trial NCT04211337, it was granted accelerated FDA approval on May 8, 2020, for specific RET-driven cancer indications. It is currently marketed under the brand name RETEVMO™ by Loxo Oncology Inc. Selpercatinib is also approved by the European Commission.
Prednisone {u} (Compound) resembles {v} (Compound) Triamcinolone
Prednisone {u} (Compound) resembles {v} (Compound) Testolactone
Prednisone {u} (Compound) treats {v} (Disease) psoriasis
Prednisone {u} (Compound) binds {v} (Gene) CYP3A4
Prednisone {u} (Compound) upregulates {v} (Gene) VAPB
Prednisone {u} (Compound) palliates {v} (Disease) osteoarthritis
Prednisone {u} (Compound) is included by {v} (Pharmacologic Class) Corticosteroid Hormone Receptor Agonists
Prednisone {u} (Compound) downregulates {v} (Gene) ZDHHC6
Prednisone {u} (Compound) causes {v} (Side Effect) Arthralgia
Prednisone {u} may cause a minor interaction that can limit clinical effects when taken with {v} Aluminum hydroxide
Prednisone (Compound) resembles Triamcinolone (Compound)
Prednisone (Compound) resembles Testolactone (Compound)
Prednisone (Compound) treats psoriasis (Disease)
Prednisone (Compound) binds CYP3A4 (Gene)
Prednisone (Compound) upregulates VAPB (Gene)
Prednisone (Compound) palliates osteoarthritis (Disease)
Prednisone (Compound) is included by Corticosteroid Hormone Receptor Agonists (Pharmacologic Class)
Prednisone (Compound) downregulates ZDHHC6 (Gene)
Prednisone (Compound) causes Arthralgia (Side Effect)
Prednisone may cause a minor interaction that can limit clinical effects when taken with Aluminum hydroxide